Michael Wang
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Wang, Michael; Ramchandren, Radhakrishnan; Chen, Robert; Karlin, Lionel; Chong, Geoffrey; Jurczak, Wojciech; Wu, Ka Lung; Bishton, Mark; Collins, Graham P.; Peyrade, Frédéric; Lee, Yihua; Neuenburg, Jutta K.; Tam, Constantine S.
Authors
Radhakrishnan Ramchandren
Robert Chen
Lionel Karlin
Geoffrey Chong
Wojciech Jurczak
Ka Lung Wu
Mark Bishton
Graham P. Collins
Frédéric Peyrade
Yihua Lee
Jutta K. Neuenburg
Constantine S. Tam
Abstract
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform whether an ibrutinib lead-in should be implemented for the randomized portion. Patients received concurrent ibrutinib 560mg continuously plus venetoclax in a 5-week ramp-up to venetoclax 400mg for up to 2years. The primary endpoint was occurrence of tumor lysis syndrome (TLS) and dose-limiting toxicities (DLTs). The SRI cohort enrolled 21 patients; six and 15 were in low- or increased-risk categories for TLS, respectively. During the 5-week venetoclax ramp-up, three patients had DLTs, and one patient at increased risk for TLS had a laboratory TLS; no additional TLS events occurred during follow-up. With a median follow-up of 31months, the overall response rate was 81% (17/21); 62% (13/21) of patients had a complete response. SRI data informed that the randomized portion should proceed with concurrent ibrutinib plus venetoclax, with no ibrutinib lead-in. Ibrutinib plus venetoclax demonstrated promising efficacy; no new safety signals were observed. Trial registration: ClinicalTrials.gov, NCT03112174. Registered 13 April 2017, https://clinicaltrials.gov/ct2/show/NCT03112174.
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 21, 2021 |
Online Publication Date | Oct 30, 2021 |
Publication Date | 2021-10 |
Deposit Date | Aug 1, 2023 |
Publicly Available Date | Aug 8, 2023 |
Journal | Journal of Hematology & Oncology |
Electronic ISSN | 1756-8722 |
Peer Reviewed | Peer Reviewed |
Volume | 14 |
Article Number | 179 |
DOI | https://doi.org/10.1186/s13045-021-01188-x |
Keywords | Cancer Research; Oncology; Molecular Biology; Hematology |
Public URL | https://nottingham-repository.worktribe.com/output/23550358 |
Publisher URL | https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01188-x |
PMID | 34717692 |
Files
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
(1.1 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search